Braidwell LP boosted its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 148.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 1,284,472 shares of the company’s stock after buying an additional 767,242 shares during the quarter. Braidwell LP’s holdings in Arvinas were worth $31,637,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its stake in Arvinas by 137.2% during the second quarter. SG Americas Securities LLC now owns 86,096 shares of the company’s stock worth $2,292,000 after acquiring an additional 49,799 shares during the last quarter. Candriam S.C.A. boosted its position in shares of Arvinas by 32.0% during the second quarter. Candriam S.C.A. now owns 610,458 shares of the company’s stock worth $16,250,000 after buying an additional 147,904 shares during the period. Magnetar Financial LLC boosted its position in shares of Arvinas by 112.7% during the second quarter. Magnetar Financial LLC now owns 41,992 shares of the company’s stock worth $1,118,000 after buying an additional 22,245 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Arvinas by 32.6% during the second quarter. Bank of New York Mellon Corp now owns 235,096 shares of the company’s stock worth $6,258,000 after buying an additional 57,835 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Arvinas during the third quarter worth $3,442,000. Institutional investors and hedge funds own 95.19% of the company’s stock.
Arvinas Price Performance
Shares of NASDAQ:ARVN opened at $25.98 on Friday. The business’s 50 day simple moving average is $25.66 and its 200-day simple moving average is $26.81. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of -5.56 and a beta of 1.96. Arvinas, Inc. has a 12 month low of $21.17 and a 12 month high of $53.08.
Analyst Ratings Changes
Several research analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research report on Monday, September 9th. Stephens began coverage on Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price for the company. Oppenheimer decreased their target price on Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. BMO Capital Markets decreased their price target on Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a report on Wednesday, November 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $87.00 price target on shares of Arvinas in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.08.
View Our Latest Stock Report on ARVN
About Arvinas
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Further Reading
- Five stocks we like better than Arvinas
- Stock Average Calculator
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- About the Markup Calculator
- 3 Penny Stocks Ready to Break Out in 2025
- What is Put Option Volume?
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas, Inc. (NASDAQ:ARVN – Free Report).
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.